Ovagen
EDL peptide, Glu-Asp-Leu, liver and gastrointestinal bioregulator
Ovagen is sold as a liver and gastrointestinal peptide bioregulator from the Khavinson series. Despite the name, it is not marketed for ovarian tissue. The EDL tripeptide has been studied in exactly one identifiable published experiment, and that experiment used ageing kidney cells, not liver or gut. There is no research on the organ system it is sold for.
Mechanism
There is one published experimental context for this peptide and it does not concern liver or gut. The claimed mechanism is the generic Khavinson model transposed to hepatic and gastrointestinal tissue: nuclear entry by a short peptide, direct interaction with promoter DNA, and tissue-selective regulation of protein synthesis, supposedly normalising hepatocyte and enterocyte function and supporting regeneration after injury.
What has actually been measured is different. In a 2014 study in ageing renal cell culture, EDL was reported to increase cell proliferation, decrease expression of the senescence markers p16, p21 and p53 and increase expression of SIRT6, with accompanying molecular models proposing that the peptide forms its most energetically favourable complexes with alternating AT sequences in the DNA minor groove. Those are cell-culture and modelling results in kidney cells. Nothing in them speaks to hepatocytes, enterocytes or any digestive function.
The name is itself a source of confusion worth flagging. 'Ovagen' suggests ovarian tissue and is sometimes marketed on that basis, while most vendor descriptions assign it to liver and gut, and the only published data concern kidney. That the target organ is not settled even among the sellers is a reasonable indication of how much experimental grounding exists behind the assignment.
As with the rest of the series, the fundamental unanswered question is how a three-residue peptide could encode organ-selective recognition. Three amino acids provide a very small amount of sequence information, and no structural work has demonstrated selective binding of EDL to any hepatic or intestinal regulatory element.
What the research shows
We identified exactly one published experimental study of this peptide: a 2014 Russian-language paper in Advances in Gerontology reporting that the tripeptides AED and EDL slowed markers of ageing in renal cell culture, increasing proliferation, reducing p16, p21 and p53 expression and raising SIRT6, alongside in silico DNA-binding models. There are no animal studies, no pharmacokinetics, no toxicology and no clinical trials. A PubMed title and abstract search for 'ovagen' returns records concerning ovarian physiology, follicle-stimulating hormone in dairy cattle and other unrelated topics. No registered clinical trial exists.
The irony is worth stating plainly, because it is the most useful thing a reader can take away. A compound named after the ovary, sold for the liver and gut, has been tested only in kidney cells. That is not a research base supporting a hepatic product; it is a single unreplicated cell-culture experiment in a different organ system entirely, published in a journal with limited international readership by the group that sells the theory.
The supporting literature otherwise offered by sellers consists of general papers about the Khavinson series, particularly work reporting tissue-selective effects in organotypic culture and chromatin changes in lymphocytes from elderly donors. These do not test EDL and cannot substitute for compound-specific data.
For a compound marketed for liver support, the absence of hepatic data has a specific edge. Liver disease is common, frequently asymptomatic until advanced, and has treatments whose benefit depends on early initiation. A product presented as hepatoprotective on no hepatic evidence risks both direct harm, since hepatic clearance of an uncharacterised compound is itself unstudied, and the indirect harm of delayed proper assessment.
Evidence assessment
Preclinical only
The single identifiable compound-specific study is an unreplicated cell-culture experiment in renal cells from the originating network; there is no data in the liver or gastrointestinal tissue the compound is sold for, and no animal or human work of any kind.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Tripeptides slow down aging process in renal cell culture Preclinical only
The peptides AED and EDL increased cell proliferation, decreased expression of the ageing markers p16, p21 and p53 and increased SIRT6 expression; modelling suggested most favourable binding to alternating AT sequences in the DNA minor groove.
Effects of short peptides on lymphocyte chromatin in senile subjects Preclinical only
Short peptides were reported to alter heterochromatin structure in lymphocytes from elderly subjects.
Safety
Entirely uncharacterised. No toxicology, no animal safety study, no human exposure record. A specific concern for a compound marketed as hepatoprotective is that nothing is known about its hepatic handling or about interactions with liver disease. Material sold online is unregulated and, absent a published reference standard, cannot be verified for identity or purity.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation. Supply for human use engages the Human Medicines Regulations 2012 regardless of a 'research use only' label. |
| United States | Not approved by the FDA, never studied under an investigational new drug application, absent from clinical trial registries. Sold as a research chemical. |
| WADA (sport) | Not individually named on the Prohibited List but captured by section S0 (non-approved substances), prohibited at all times. |
Questions
Most vendor descriptions assign it to liver and gastrointestinal tissue despite the name. The only published experiment on the EDL peptide used kidney cells. That the target organ is inconsistent across the name, the sellers and the literature is itself a signal of how little experimental grounding the assignment has.
One study. A 2014 Russian-language paper reported that EDL and a related tripeptide reduced senescence markers and increased proliferation in ageing renal cell culture. There are no animal studies, no pharmacokinetics, no toxicology and no clinical trials, and nothing at all in liver or gut.
There is no evidence for this. No study has examined its effect on any measure of liver function in any species, and nothing is known about how the liver handles the compound itself.
The described mechanism is borrowed wholesale from the general Khavinson model and applied by analogy to liver and gut. It reflects a theoretical framework, not experiments performed on this molecule in those tissues.